Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Blinatumomab as consolidation for adult B-ALL

Irene Urbino • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

Irene Urbino, MD, Città della Salute e della Scienza di Torino, Turin, Italy discusses the efficacy of blinatumomab given as consolidation in adults with B-cell precursor acute lymphoblastic leukemia (B-ALL). Dr Urbino describes how, in this real-world evidence study, patients with B-ALL were divided into three subgroups – those in first complete remission (CR1), those in second CR after chemotherapy-base salvage therapy (CR2), and those in overt relapse (R/R). The results of the study highlight that blinatumomab should preferably be used in consolidation rather than as salvage therapy in patients with B-ALL in first relapse. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Irene Urbino

1:35
Maintenance & consolidation strategies for ALL and their impact on QoL
Irene Urbino • 12 Jun 2022
1:36
Chemotherapy and alloHSCT in the treatment of ALL
Irene Urbino • 12 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals